染色质、癌症与药物疗法。
Chromatin, cancer and drug therapies.
作者信息
Cortez Connie C, Jones Peter A
机构信息
Department of Urology, University of Southern California, Los Angeles, CA 90089-9181, USA.
出版信息
Mutat Res. 2008 Dec 1;647(1-2):44-51. doi: 10.1016/j.mrfmmm.2008.07.006. Epub 2008 Jul 22.
Abstract
The structure and organization of chromatin have attracted a great deal of attention recently because of their implications for the field of epigenetics. DNA methylation and the post-translational modifications that occur on histones can specify transcriptional competency. During cancer development, tumor suppressor genes become silenced by DNA hypermethylation and chromatin modifiers no longer perform in their usual manner. Current epigenetic therapy has been able to take advantage of the reversibility of these epimutations. Progress has been made in the treatment of hematological malignancies and some solid tumors. As the knowledge of how chromatin regulates gene expression is enhanced, improvements in the treatment of cancer can be made.
摘要
由于染色质的结构和组织对表观遗传学领域具有重要意义，它们最近备受关注。DNA甲基化以及发生在组蛋白上的翻译后修饰能够决定转录活性。在癌症发展过程中，肿瘤抑制基因会因DNA高甲基化而沉默，染色质修饰因子也不再以其通常的方式发挥作用。目前的表观遗传疗法能够利用这些表观突变的可逆性。在血液系统恶性肿瘤和一些实体瘤的治疗方面已经取得了进展。随着对染色质如何调节基因表达的认识不断加深，癌症治疗有望得到改善。
相似文献
1
Chromatin, cancer and drug therapies.染色质、癌症与药物疗法。
Mutat Res. 2008 Dec 1;647(1-2):44-51. doi: 10.1016/j.mrfmmm.2008.07.006. Epub 2008 Jul 22.
2
Epigenetics in cancer: targeting chromatin modifications.癌症中的表观遗传学：靶向染色质修饰
Mol Cancer Ther. 2009 Jun;8(6):1409-20. doi: 10.1158/1535-7163.MCT-08-0860. Epub 2009 Jun 9.
3
Epigenetic therapy of cancer with histone deacetylase inhibitors.用组蛋白去乙酰化酶抑制剂进行癌症的表观遗传治疗。
J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937.
4
Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.抑制DNA甲基化和组蛋白去乙酰化的表观遗传活性药物
Curr Pharm Des. 2017;23(8):1167-1174. doi: 10.2174/1381612822666161021110827.
5
Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.组蛋白去乙酰化酶抑制剂：作为临床应用前提的分子与生物学活性
Curr Drug Metab. 2007 May;8(4):383-93. doi: 10.2174/138920007780655397.
6
Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.表观遗传调节剂作为多种癌症的治疗替代方案
Curr Med Chem. 2022;29(9):1503-1542. doi: 10.2174/0929867329666211228111036.
7
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.表观遗传药物作为癌症治疗中的多效性药物：生物分子方面及临床应用
J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066.
8
[Targeted epigenetic therapy of cancer. Achievements and perspectives].[癌症的靶向表观遗传治疗。成就与展望]
Cir Cir. 2012 Sep-Oct;80(5):470-80.
9
Epigenetic Therapies and Potential Drugs for Treating Human Cancer.表观遗传学治疗及其治疗人类癌症的潜在药物。
Curr Drug Targets. 2020;21(11):1068-1083. doi: 10.2174/1389450121666200325093104.
10
Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.表观遗传学治疗：组蛋白乙酰化、DNA 甲基化和抗癌药物发现。
Curr Cancer Drug Targets. 2009 Dec;9(8):963-81. doi: 10.2174/156800909790192428.
引用本文的文献
1
Mass Spectrometry Contribution to Pediatric Cancers Research.质谱技术在儿科癌症研究中的应用
Medicina (Kaunas). 2023 Mar 20;59(3):612. doi: 10.3390/medicina59030612.
2
Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer.化合物 C620-0696，一种针对 BPTF 的新型强效抑制剂，BPTF 是一种非小细胞肺癌中的染色质重塑因子。
Front Med. 2020 Feb;14(1):60-67. doi: 10.1007/s11684-019-0694-8. Epub 2019 May 18.
3
Epigenetic mechanisms as a new approach in cancer treatment: An updated review.表观遗传机制作为癌症治疗的新方法：最新综述。
Genes Dis. 2018 Jun 18;5(4):304-311. doi: 10.1016/j.gendis.2018.06.003. eCollection 2018 Dec.
4
Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells.CD1d表达的表观遗传诱导使肺癌细胞对不变自然杀伤T细胞的杀伤作用致敏。
Oncoimmunology. 2018 Feb 12;7(6):e1428156. doi: 10.1080/2162402X.2018.1428156. eCollection 2018.
5
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.辛二酰苯胺异羟肟酸通过重新激活肿瘤抑制性微小RNA来抑制头颈癌细胞系的生长。
Oral Oncol. 2016 May;56:32-9. doi: 10.1016/j.oraloncology.2016.02.015. Epub 2016 Mar 19.
6
Common stemness regulators of embryonic and cancer stem cells.胚胎干细胞和癌症干细胞常见的干性调节因子。
World J Stem Cells. 2015 Oct 26;7(9):1150-84. doi: 10.4252/wjsc.v7.i9.1150.
7
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.组蛋白去乙酰化酶抑制剂与淋巴系统恶性肿瘤中的表观遗传调控
Invest New Drugs. 2015 Dec;33(6):1280-91. doi: 10.1007/s10637-015-0290-y. Epub 2015 Sep 30.
8
Comparison of the anti-cancer effect of Disulfiram and 5-Aza-CdR on pancreatic cancer cell line PANC-1.双硫仑与5-氮杂-2'-脱氧胞苷对胰腺癌细胞系PANC-1抗癌作用的比较。
Adv Biomed Res. 2014 Jul 31;3:156. doi: 10.4103/2277-9175.137866. eCollection 2014.
9
Regulation of microRNAs by epigenetics and their interplay involved in cancer.表观遗传学对微小RNA的调控及其在癌症中的相互作用。
J Exp Clin Cancer Res. 2013 Nov 22;32(1):96. doi: 10.1186/1756-9966-32-96.
10
Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach.微小RNA-29b恢复人乳腺癌中高甲基化基因启动子的甲基化状态：一种新的表观遗传治疗方法。
J Carcinog. 2013 Jul 26;12:15. doi: 10.4103/1477-3163.115720. eCollection 2013.
本文引用的文献
1
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.长期口服泽布替尼进行表观遗传治疗副作用极小，并可预防小鼠肠道肿瘤。
Cancer Prev Res (Phila). 2008 Sep;1(4):233-40. doi: 10.1158/1940-6207.CAPR-07-0008. Epub 2008 Mar 19.
2
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.MG98（一种针对DNA甲基转移酶1的寡脱氧核苷酸反义药物）在高危骨髓增生异常综合征和急性髓系白血病患者中的I期生物学研究。
Clin Cancer Res. 2008 Apr 15;14(8):2444-9. doi: 10.1158/1078-0432.CCR-07-1320.
3
Epigenetic interplay between histone modifications and DNA methylation in gene silencing.基因沉默中组蛋白修饰与DNA甲基化之间的表观遗传相互作用。
Mutat Res. 2008 Jul-Aug;659(1-2):40-8. doi: 10.1016/j.mrrev.2008.02.004. Epub 2008 Feb 29.
4
Dynamic remodeling of individual nucleosomes across a eukaryotic genome in response to transcriptional perturbation.真核生物基因组中单个核小体响应转录扰动的动态重塑。
PLoS Biol. 2008 Mar 18;6(3):e65. doi: 10.1371/journal.pbio.0060065.
5
Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.组蛋白去乙酰化酶抑制剂缩酚酸肽通过降低启动子上的CpG和H3K9甲基化来激活沉默基因。
Mol Cell Biol. 2008 May;28(10):3219-35. doi: 10.1128/MCB.01516-07. Epub 2008 Mar 10.
6
Dynamic regulation of nucleosome positioning in the human genome.人类基因组中核小体定位的动态调控
Cell. 2008 Mar 7;132(5):887-98. doi: 10.1016/j.cell.2008.02.022.
7
Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.苯丁酸盐干扰范可尼贫血和BRCA通路，并使头颈癌细胞对顺铂敏感。
Mol Cancer. 2008 Mar 6;7:24. doi: 10.1186/1476-4598-7-24.
8
Meeting report: myelodysplastic syndromes at ASH 2007.会议报告：2007年美国血液学会年会的骨髓增生异常综合征
Leukemia. 2008 May;22(5):893-7. doi: 10.1038/leu.2008.45. Epub 2008 Mar 6.
9
Depsipeptide (FK228) inhibits growth of human prostate cancer cells.环缩肽（FK228）抑制人前列腺癌细胞的生长。
Urol Oncol. 2008 Mar-Apr;26(2):182-9. doi: 10.1016/j.urolonc.2007.01.020. Epub 2007 Nov 19.
10
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.伏立诺他治疗持续性或复发性上皮性卵巢癌或原发性腹膜癌的II期研究：一项妇科肿瘤学组研究
Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.
Zotero 插件